federal employees during a competition if the facilities and employees are made equitably available to all individuals and entities participating in the competition;
(12) Must provide a statement agreeing to indemnify the federal government against third party claims for damages arising from or related to competition activities;
(13) Must provide a statement agreeing to assume all risks and waive claims against the Federal Government and its related entities, except in the case of willful misconduct, for any injury, death, damage, or loss of property, revenue, or profits, whether direct, indirect, or consequential, arising from participation in this prize contest, whether the injury, death, damage, or loss arises through negligence or otherwise.
(14) HHS has hereby waived the requirement for participants to obtain liability insurance in a specified amount for this competition. Participants are advised to consult with appropriate advisors to determine what amounts of insurance may be necessary for their own liability protection.
Additional Requirements
Entrainds shall not use the OWH or HHS logos or official seals in their submissions, and must not claim endorsement.
HHS reserves the right to cancel, suspend, and/or modify the Shape of Health competition, or any part of it, for any reason, at HHS’ sole discretion.
Payment of the Prize: Prizes awarded under this competition will be paid by electronic funds transfer and may be subject to Federal income taxes. HHS will comply with the Internal Revenue Service withholding and reporting requirements, where applicable.

Intellectual Property (IP)
- Each entrant retains full ownership and title in and to their submission. Entrants expressly reserve all intellectual property rights not expressly granted under this publication notice.
- By participating in the competition, each entrant hereby irrevocably grants to HHS a limited, non-exclusive, royalty-free, worldwide license and right to reproduce, publicly perform, publicly display, and use the submission for internal HHS business and to the extent necessary to administer the competition, and to publicly perform and publicly display the submission, including, without limitation, for advertising and promotional purposes relating to the competition.
- Record Retention and FOIA: All materials submitted to HHS as part of a submission become HHS records and cannot be returned. Any confidential commercial information contained in a submission should be designated at the time of submission. Participants will be notified of any Freedom of Information Act requests for their submissions in accordance with 45 CFR 5.65.

SUPPLEMENTARY INFORMATION:
Information on obesity prevention and control in women and girls can be found at:
https://www.cdc.gov/obesity/resources/strategies-guidelines.html
https://www.womenshealth.gov/a-z-topics/overweight-obesity-and-weight-loss
https://www.girlshealth.gov/nutrition/healthyweight/
Details on the Shape of Health competition may be found at challenge.gov.

FOR FURTHER INFORMATION CONTACT: Ann Abercrombie at Ann.Abercrombie@hhs.gov.
Dated: November 28, 2018.
Brett Giroir,
ADM, Assistant Secretary for Health.

BILLING CODE 4150–33–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: “Multifunctional RNA Nanoparticles and Methods of Uses” and “RNA/DNA Hybrid Nanoparticles Modified With Single Stranded RNA Toeholds and Uses Thereof”

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to Sixfold Biosciences Inc., (“Sixfold”) of Walnut, California.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before January 7, 2019 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Jasmine Yang, Sr. Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850–9702 Telephone: (240)–276–5530; Facsimile: (240)–276–5504 Email: jasmine.yang@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property
A. Multifunctional RNA Nanoparticles and Methods of Uses


B. RNA/DNA Hybrid Nanoparticles Modified With Single Stranded RNA Toeholds and Uses Thereof


DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke, Interagency Pain Research Coordinating Committee Call for Committee Membership Nominations
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) (Department) has created the Interagency Pain Research Coordinating Committee (IPRCC) and is seeking nominations for this committee.

DATES: Nominations are due by 5 p.m. on January 25, 2019.

ADDRESSES: Nominations must be submitted through the webform on the IPRCC website: https://iprcc.nih.gov/About/Membership-Agency-Representation/Nomination-Form.

FOR FURTHER INFORMATION CONTACT: Linda Porter at 301–451–4460 or email porterl@ninds.nih.gov.

SUPPLEMENTARY INFORMATION: As specified in Public Law 111–148 (“Patient Protection and Affordable Care Act”) and amended in H.R. 6, (“Support for Patients and Communities Act”) the Committee will:
(A) Develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration;
(B) identify critical gaps in basic and clinical research on
(i) the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain;
(ii) the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and
(iii) risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain;
(C) make recommendations to the Director of NIH
(i) to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;
(ii) on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and
(iii) on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

Membership on the committee will include six (6) non-Federal members from among scientists, physicians, and other health professionals and six (6) non-Federal members of the general public who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions. Members will serve overlapping three year terms. It is anticipated that the committee will meet at least once a year.

The Department strives to ensure that the membership of HHS Federal advisory committees is fairly balanced in terms of points of view represented and the committee’s function. Every effort is made to ensure that the views of diverse ethnic and racial groups and people with disabilities are represented on HHS Federal advisory committees, and the Department therefore, encourages nominations of qualified candidates from these groups. The Department also encourages geographic diversity in the composition of the Committee. Appointment to this Committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status.

The Department is soliciting nominations for 5 non-federal members from among scientists, physicians, and other health professionals and for 3 non-federal members of the general public who represent a leading research, advocacy, or service organization for people with pain-related conditions. These candidates will be considered to fill positions opened through completion of current member terms. Nominations are due by 5 p.m. on January 25, 2019, using the IPRCC nomination webform: https://iprcc.nih.gov/About/Membership-Agency-Representation/Nomination-Form.

Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health.

[FR Doc. 2018–27737 Filed 12–20–18; 8:45 am]
BILLING CODE 4140–01–P